Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Akichika Ozeki
A 1-Year Safety Study of Dulaglutide in Japanese Patients With Type 2 Diabetes on a Single Oral Hypoglycemic Agent: An Open-Label, Nonrandomized, Phase 3 Trial
Endocrine Journal
Endocrinology
Metabolism
Diabetes
Related publications
Efficacy and Safety of Repaglinide Added to Sitagliptin in Japanese Patients With Type 2 Diabetes: A Randomized 24-Week Open-Label Clinical Trial
Endocrine Journal
Endocrinology
Metabolism
Diabetes
Efficacy and Safety of Dulaglutide in the Treatment of Type 2 Diabetes: A Comprehensive Review of the Dulaglutide Clinical Data Focusing on the AWARD Phase 3 Clinical Trial Program
Diabetes/Metabolism Research and Reviews
Internal Medicine
Endocrinology
Metabolism
Diabetes
Efficacy and Safety of Dulaglutide Monotherapy Versus Metformin in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-3)
Diabetes Care
Internal Medicine
Endocrinology
Advanced
Metabolism
Specialized Nursing
Diabetes
Efficacy and Safety of Ipragliflozin Add‐on Therapy to Insulin in Japanese Patients With Type 1 Diabetes Mellitus: A Randomized, Double‐blind, Phase 3 Trial
Diabetes, Obesity and Metabolism
Internal Medicine
Endocrinology
Metabolism
Diabetes
Association Between Use of Oral Hypoglycemic Agents in Japanese Patients With Type 2 Diabetes Mellitus and Risk of Depression: A Retrospective Cohort Study
Proceedings for Annual Meeting of The Japanese Pharmacological Society
Association Between Use of Oral Hypoglycemic Agents in Japanese Patients With Type 2 Diabetes Mellitus and Risk of Depression: A Retrospective Cohort Study
Pharmacology Research and Perspectives
Toxicology
Neurology
Pharmaceutics
Pharmacology
Efficacy of Combination Therapy With Insulin and Oral Hypoglycemic Agents in Patients With Type II Diabetes During a 1-Year Period
Journal of the American Osteopathic Association, The
Medicine
Alternative Medicine
Complementary
Long-Term Safety and Tolerability of Oral Tofacitinib in Patients With Crohn’s Disease: Results From a Phase 2, Open-Label, 48-Week Extension Study
Alimentary Pharmacology and Therapeutics
Hepatology
Pharmacology
Gastroenterology
A Phase III, Multicenter, Collaborative, Open-Label Clinical Trial of Sildenafil in Japanese Patients With Pulmonary Arterial Hypertension
Circulation Journal
Medicine
Cardiovascular Medicine
Cardiology
